Literature DB >> 27832661

Identifying Predictors of Anti-VEGF Treatment Response in Patients with Neovascular Age-Related Macular Degeneration through Discriminant and Principal Component Analysis.

Frank G Holz1, Ramin Tadayoni, Stephen Beatty, Alan R Berger, Matteo G Cereda, Philip Hykin, Carel B Hoyng, Kim Wittrup-Jensen, Andreas Altemark, Jonas Nilsson, Kun Kim, Sobha Sivaprasad.   

Abstract

OBJECTIVE: AURA was an observational study that monitored visual acuity outcomes following ranibizumab use in neovascular age-related macular degeneration patients over 2 years. The aim of this analysis was to identify factors that were predictive of visual acuity outcomes in AURA.
METHODS: The correlation between the baseline characteristics, the use of resources and the visual acuity outcomes in AURA was explored using principal component analysis (PCA) and partial least-squares-discriminant analysis (PLS-DA). The response variables analysed were mean change in visual acuity over 2 years (analysed via PCA) and no decline in visual acuity at 2 years compared with baseline (analysed via PLS-DA).
RESULTS: The AURA dataset comprised 2,227 patients and 132 variables. Using PCA and PLS-DA, we found that the number of ranibizumab injections, clinic and monitoring visits, number of optical coherence tomography scans and ophthalmoscopies correlated with a change in visual acuity at Years 1 and 2, and are therefore key drivers of treatment success.
CONCLUSION: This is a novel approach to graphically explore relationships between multiple correlated covariates and outcomes in real-life ophthalmology studies. It identified a number of variables that are positively linked with treatment outcomes.
© 2016 S. Karger AG, Basel.

Entities:  

Keywords:  AURA; Intravitreal ranibizumab; Neovascular age-related macular degeneration

Mesh:

Substances:

Year:  2016        PMID: 27832661     DOI: 10.1159/000449001

Source DB:  PubMed          Journal:  Ophthalmic Res        ISSN: 0030-3747            Impact factor:   2.892


  2 in total

1.  Association of Genetic Variants With Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration.

Authors:  Laura Lorés-Motta; Moeen Riaz; Michelle Grunin; Jordi Corominas; Freekje van Asten; Marc Pauper; Mathieu Leenders; Andrea J Richardson; Philipp Muether; Angela J Cree; Helen L Griffiths; Connie Pham; Marie-Claude Belanger; Magda A Meester-Smoor; Manir Ali; Iris M Heid; Lars G Fritsche; Usha Chakravarthy; Richard Gale; Martin McKibbin; Chris F Inglehearn; Reinier O Schlingemann; Amer Omar; John Chen; Robert K Koenekoop; Sascha Fauser; Robyn H Guymer; Carel B Hoyng; Eiko K de Jong; Andrew J Lotery; Paul Mitchell; Anneke I den Hollander; Paul N Baird; Itay Chowers
Journal:  JAMA Ophthalmol       Date:  2018-08-01       Impact factor: 7.389

2.  Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study.

Authors:  Richard P Gale; Ian Pearce; Nicole Eter; Faruque Ghanchi; Frank G Holz; Steffen Schmitz-Valckenberg; Konstantinos Balaskas; Ben J L Burton; Susan M Downes; Haralabos Eleftheriadis; Sheena George; David Gilmour; Robin Hamilton; Andrew J Lotery; Nishal Patel; Priya Prakash; Cynthia Santiago; Saju Thomas; Deepali Varma; Gavin Walters; Michael Williams; Armin Wolf; Rosina H Zakri; Franklin Igwe; Filis Ayan
Journal:  Br J Ophthalmol       Date:  2019-08-05       Impact factor: 4.638

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.